Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. [electronic resource]
Producer: 20111024Description: 3389-95 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bendamustine Hydrochloride
- Boronic Acids -- administration & dosage
- Bortezomib
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Follicular -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Nitrogen Mustard Compounds -- administration & dosage
- Pyrazines -- administration & dosage
- Rituximab
- Salvage Therapy
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.